Tenax Therapeutics is a specialty pharmaceutical company that is dedicated to improving the lives of patients by developing groundbreaking therapies. They follow a patient-centric and precision medicine approach, focusing on identifying and developing therapeutics for cardio-pulmonary diseases with high unmet medical needs. Their primary focus is on pulmonary hypertension, a condition with limited treatment options and low survival rates.

They aim to address this challenge by developing innovative and highly efficient clinical trial designs. Tenax Therapeutics offers two key products: TNX-201, an oral enteric-coated imatinib, and TNX-103, an oral levosimendan. Both products have the potential to revolutionize the treatment of pulmonary hypertension and provide hope to patients.

Stay updated on their latest news and learn more about their work through their education center and featured articles. Contact Tenax Therapeutics to join their mission of transforming the lives of patients through their pioneering therapies